<DOC>
	<DOCNO>NCT01958463</DOCNO>
	<brief_summary>Recent data demonstrate beneficial health outcome microbiota transplantation treatment Clostridium Difficile infection . The investigator propose test whether fecal transplantation healthy donor lead recovery Clostridium Difficile recurrent/treatment-resistant infection .</brief_summary>
	<brief_title>Transplantation Fecal Microbiota Clostridium Difficile Infection</brief_title>
	<detailed_description>Infections Clostridium Difficile common community among hospitalized patient . It mostly prevalent follow antibiotic treatment . In recent year investigator witness increase severity , incidence treatment-resistant case . Treatment-resistant infection recurrent infection put patient risk severe complication , perforation , septic shock , megacolon even death . New antibiotic treatment Rifaximin Fidaxomicin yet available routine use Israel . It know normal intestinal microbiota protect Clostridium Difficile infection , early 1958 , researcher demonstrate transplantation fecal microbiota beneficial effect Clostridium Difficile Infection . In fact , previous data show microbiota transplantation colonoscopy , patient treatment-resistant infection recurrent infection , effective method 90 % success rate single treatment . The investigator propose test whether fecal transplantation healthy donor lead recovery Clostridium Difficile infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>age &gt; 18 year . A negative pregnancy test inclusion , commitment use contraception period six month date transplant . At least one follow condition : 1 . An evidence Clostridium infection recurrence within 6 month completion antibiotic course acceptable , include least 10 day treatment Bmtronidzol total dose 500 mg x3 per day / Bonkomitzin dose least 125 mg 4x day . Recurrence infection define clinical laboratory : ≥ 3 diarrhea per day least two day row ≥ 8 loose stool day 48 hour . positive stool test Clostridium Difficile toxin , PCR / antigen detection . 2 . First infection respond antibiotic ( least 10 day Metronidazole dosage 1500 mg per day , Bonkomitzin total dose least 500 mg per day ) . 3 . A first infection patient intolerant allergic Lonkomitzin metronidazole . Participation another clinical study . Inability provide inform consent . A pregnant woman breastfeed . Severe neutropenia 500 neutrophil ( blood count ) . A significant immunosuppression ( SCID , CVID , GVHD , use different preparation Aimonosofrsibiim , include prolonged corticosteroid therapy dose equivalent ≥ 20 mg prednisone per day 4 week ) . Status SIRS hemodynamic/respiratory instability . Toxic Megacolon , ischemic colitis , Fulminant colitis high usual risk colon perforatin colonoscopy . HBV infection hepatitis C HIV . The use antibiotic treatment another disease time inclusion . A history previous current autoimmune disease , progressive/an uncontrolled disease kidney/liver/hematological system/endocrine system/ heart/neurological system , metabolic disease . An addiction alcohol drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Clostridium Difficile Infection</keyword>
	<keyword>Fecal Microbiota Transplantation</keyword>
</DOC>